An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
Key Details
- 1Research presented at RSNA 2025 evaluated the Koios DS AI tool for breast ultrasound.
- 2The study involved 14 breast imaging radiologists and 271 lesions in 253 women, with 76.8% benign and 23.2% malignant lesions.
- 3The AI tool showed 60.6% specificity, assigning many benign lesions to lower BI-RADS categories, and a sensitivity of 90.5%.
- 4The tool misclassified 6 malignant lesions, most of which had other imaging correlates.
- 5Experts emphasized the AI should be used as an adjunct, not a replacement, to radiologist judgment for biopsy decisions.
Why It Matters
Reducing unnecessary biopsies can lower patient anxiety, cut healthcare costs, and ease operational burdens on imaging practices. Integrating AI as a decision-support tool alongside radiologists could lead to more accurate, efficient, and patient-centered breast imaging workflows.
Source
AuntMinnie
Related News
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.
•AuntMinnie
SIIM Study: LLMs Excel in Numerical Radiology Tasks
At SIIM 2026, LLMs demonstrated high accuracy on radiology-based numerical tasks, particularly in extraction and judgment tests.